About 90% of CMML patients carry genomic aberrations, which includes mutations in genes encoding for epigenetic regulators (TET2, ASXL1, DNMT3A, EZH2, IDH1, IDH2), spliceosome components (SRSF2, SF3B1, ZRSF2, U2AF1), transcription factors (RUNX1, NPM1, TP53) and other signaling molecules (NRAS, KRAS, CBL, JAK2, FLT3) [11]. Here, EZH2 is linked to chronic myelomonocytic leukemia.